FRHC:NASDAQFreedom Holding Corp. Analysis
Data as of 2026-05-20 - not real-time
$147.06
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Freedom Holdings Corp. is trading below its 20‑day and 50‑day moving averages, with the price sitting beneath the 200‑day average, indicating a prevailing bearish bias. The RSI sits in the mid‑50s, suggesting neutral momentum, while the MACD shows a bullish histogram despite the line remaining below the signal, hinting at a possible short‑term reversal. Volume has been on an upward trend, providing some support for price stability, but the 30‑day volatility exceeds 45%, flagging a highly turbulent trading environment. The stock’s beta is just under one, implying market‑level systematic risk, and the historical max drawdown of over 40% underscores the downside vulnerability.
Fundamentally, the company posted a revenue decline of roughly 14% and a profit margin barely above zero, while the trailing PE is astronomically high, reflecting the current earnings base. A discounted cash‑flow model values the firm near $470, far above the current market price, which points to a substantial undervaluation gap. However, the balance sheet carries a heavy debt load with a debt‑to‑equity ratio well above 150, and return metrics (ROE, ROA) are near zero, limiting confidence in sustainable profitability. No dividend is paid, and recent regulatory scrutiny adds an extra layer of uncertainty, though the forward EPS projection suggests potential earnings improvement.
Fundamentally, the company posted a revenue decline of roughly 14% and a profit margin barely above zero, while the trailing PE is astronomically high, reflecting the current earnings base. A discounted cash‑flow model values the firm near $470, far above the current market price, which points to a substantial undervaluation gap. However, the balance sheet carries a heavy debt load with a debt‑to‑equity ratio well above 150, and return metrics (ROE, ROA) are near zero, limiting confidence in sustainable profitability. No dividend is paid, and recent regulatory scrutiny adds an extra layer of uncertainty, though the forward EPS projection suggests potential earnings improvement.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish technical alignment with price below key moving averages
- Neutral RSI and emerging bullish MACD signal
- Elevated short‑term volatility and recent regulatory focus
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant undervaluation relative to DCF fair value
- Forward EPS outlook indicating earnings recovery
- Increasing volume supporting potential price appreciation
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Long‑run upside from corrective pricing versus intrinsic value
- Potential growth from expanding digital banking and brokerage services
- Strategic diversification across multiple geographic markets
Key Metrics & Analysis
Financial Health
Revenue Growth-14.10%
Profit Margin0.18%
P/E Ratio14706.0
ROE0.22%
ROA0.03%
Debt/Equity155.89
P/B Ratio6.5
Op. Cash Flow$3.1B
Industry P/E16.6
Technical Analysis
TrendBearish
RSI53.7
Support$134.70
Resistance$154.41
MA 20$143.57
MA 50$145.81
MA 200$145.94
MACDBullish
VolumeIncreasing
Fear & Greed Index90.13
Valuation
Fair Value$469.07
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.94
Volatility47.29%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.